AIM: Metformin is the most commonly prescribed oral anti-diabetic drug in young people. It is also prescribed for polycystic ovarian syndrome (PCOS) and obesity treatment in adults in an unlicensed fashion. Little is known as to the extent metformin has been used in young people. We investigated the use of metformin in children and adolescents aged 0-18 years in the UK. METHODS: Population-based prescribing data were obtained from the UK IMS Disease Analyzer between January 2000 and December 2010. RESULTS: A total of 2674 metformin prescriptions were issued to 337 patients (80% female) between 2000 and 2010. The prevalence of metformin prescribing increased from 0.03 per 1000 person-years [95% confidence interval (CI) 0.02, 0.05] to 0.16 per 1000 person-years (95% CI 0.12, 0.20) (P= 0.001). There was a steady increase in metformin prescribing in girls aged 16-18 years. There were 290 metformin treated patients (81% female; n= 235) who had at least one diagnosis of diabetes, PCOS or obesity. Among these patients, PCOS was the most common indication for metformin prescribing in girls (n= 120) followed by diabetes. There were 22 patients (7.6%) who received metformin for obesity treatment only. CONCLUSIONS: Prescribing of metformin increased between 2000 and 2010, in particular amongst girls aged 16-18 years. The main indication for metformin prescribing was PCOS. At present, metformin is not licensed for PCOS and obesity treatment in adults or children. As there is a steady increase in the prescribing of metformin in young people, further studies are required to investigate the efficacy and safety of these prescriptions.
AIM: Metformin is the most commonly prescribed oral anti-diabetic drug in young people. It is also prescribed for polycystic ovarian syndrome (PCOS) and obesity treatment in adults in an unlicensed fashion. Little is known as to the extent metformin has been used in young people. We investigated the use of metformin in children and adolescents aged 0-18 years in the UK. METHODS: Population-based prescribing data were obtained from the UK IMS Disease Analyzer between January 2000 and December 2010. RESULTS: A total of 2674 metformin prescriptions were issued to 337 patients (80% female) between 2000 and 2010. The prevalence of metformin prescribing increased from 0.03 per 1000 person-years [95% confidence interval (CI) 0.02, 0.05] to 0.16 per 1000 person-years (95% CI 0.12, 0.20) (P= 0.001). There was a steady increase in metformin prescribing in girls aged 16-18 years. There were 290 metformin treated patients (81% female; n= 235) who had at least one diagnosis of diabetes, PCOS or obesity. Among these patients, PCOS was the most common indication for metformin prescribing in girls (n= 120) followed by diabetes. There were 22 patients (7.6%) who received metformin for obesity treatment only. CONCLUSIONS: Prescribing of metformin increased between 2000 and 2010, in particular amongst girls aged 16-18 years. The main indication for metformin prescribing was PCOS. At present, metformin is not licensed for PCOS and obesity treatment in adults or children. As there is a steady increase in the prescribing of metformin in young people, further studies are required to investigate the efficacy and safety of these prescriptions.
Authors: Antje Neubert; Katia Verhamme; Macey L Murray; Gino Picelli; Yingfen Hsia; Fatma E Sen; Carlo Giaquinto; Adriana Ceci; M Sturkenboom; Ian C K Wong Journal: Pharmacol Res Date: 2010-05-06 Impact factor: 7.658
Authors: Yingfen Hsia; Antje Neubert; Miriam C J M Sturkenboom; Macey L Murray; Katia M C Verhamme; Fatma Sen; Carlo Giaquinto; Adriana Ceci; Ian C K Wong Journal: Epilepsia Date: 2009-10-08 Impact factor: 5.864
Authors: Ramy Ayoub; Rebecca M Ruddy; Elizabeth Cox; Adeoye Oyefiade; Daniel Derkach; Suzanne Laughlin; Benjamin Ades-Aron; Zahra Shirzadi; Els Fieremans; Bradley J MacIntosh; Cynthia B de Medeiros; Jovanka Skocic; Eric Bouffet; Freda D Miller; Cindi M Morshead; Donald J Mabbott Journal: Nat Med Date: 2020-07-27 Impact factor: 53.440
Authors: S Fazeli Farsani; P C Souverein; J A Overbeek; M M J van der Vorst; C A J Knibbe; R M C Herings; A de Boer; A K Mantel-Teeuwisse Journal: Br J Clin Pharmacol Date: 2015-05-20 Impact factor: 4.335
Authors: Gitanjali Srivastava; Claudia K Fox; Aaron S Kelly; Ania M Jastreboff; Allen F Browne; Nancy T Browne; Janey S A Pratt; Christopher Bolling; Marc P Michalsky; Stephen Cook; Carine M Lenders; Caroline M Apovian Journal: Obesity (Silver Spring) Date: 2019-02 Impact factor: 5.002
Authors: Hanne Strøm; Randi Selmer; Kåre I Birkeland; Henrik Schirmer; Tore Julsrud Berg; Anne Karen Jenum; Kristian Midthjell; Christian Berg; Lars Christian Stene Journal: BMC Public Health Date: 2014-05-29 Impact factor: 3.295
Authors: M P van der Aa; M A J Elst; E M W van de Garde; E G A H van Mil; C A J Knibbe; M M J van der Vorst Journal: Nutr Diabetes Date: 2016-08-29 Impact factor: 5.097